OTIC News and Press, Otonomy Inc. From 11/30/22

3 Strategies to Know For Trading Penny Stocks Penny stocks are a popular investment choice among traders, but they can be highly volatile due to their low visibility and limited trading volume. However, by properly understanding the different trading strategies available for buying and sell...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Asia Broadband (OTCMKTS: AABB ) stock is gaining on Tuesday as investors react to news of it reaching a major ore milestone! According to a press release from the company, it finalized the...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Otonomy (NASDAQ: OTIC ) stock is on the move Tuesday despite a lack of news from the biopharmaceutical company. Instead, it looks like traders have latched onto OTIC stock as the next big ...

There’s been a brief cool-off of penny stocks under $1. One of the reasons has been the general market uncertainty thanks to mixed messages from the FOMC compared to Fed Chair Powell. A slew of economic data has also been hanging in the balance, which was seen as the catalyst...

Otonomy press release ( NASDAQ: OTIC ): Q3 GAAP EPS of -$0.18. Cash Position: Cash and cash equivalents totaled $40.1 million as of September 30, 2022, compared to $77.4 million as of December 31, 2021. Operating Expenses: GAAP operating expenses were $11.8 million for...

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended September 30, 2022 and provided an update on its produc...

Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baseline Lack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex dose-response relationship that has been observed with neurotrophins O...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

H.C. Wainwright has downgraded the neurotology-focused Otonomy, Inc. ( NASDAQ: OTIC ) to Neutral from Buy on Tuesday after the company announced that its Phase 2 trial for OTO-313 for hearing disorder tinnitus did not meet the key goals. Despite his optimism over the c...

Otonomy, Inc. (NASDAQ: OTIC) reported that the OTO-313 Phase 2 trial in tinnitus demonstrated no meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.  The phase 2 trial enrolled 153 patients with unilateral, persistent tinnitus of a...